Genomic Vision: Convening of Another Extraordinary General Meeting on October 30, 2020
22 Septembre 2020 - 7:21PM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (the “Company” - FR0011799907 –
GV), a company specialized in the development of in-vitro
diagnostic (IVD) tests for the early detection of cancers and
genetic diseases and applications for life sciences research (LSR),
informs its shareholders that, contrary to what was previously
indicated in its press release of August 10, 2020, the thirty
second resolution on the implementation of the financing line
agreed with Winance1 was not validly adopted despite the unanimous
support of shareholders who voted, insofar as the required quorum
for this specific resolution was not met.
Within this context, the Company has decided to convene another
Extraordinary General Meeting, on October 30, 2020 at 10 am CEST,
behind closed doors, whose agenda will be the adoption of this
resolution. The Company has asked the Nanterre Commercial Court to
appoint a special purpose trustee to represent the shareholders
unable to attend the Meeting, and thus ensure that the required
quorum is met.
In compliance with current legislation and the recommendations
of the AMF French stock market authority, Genomic Vision’s
shareholders are invited to exclusively express their vote
remotely, before the EGM, either via a postal vote or by granting
proxy to the Chairman of the Emergency General Meeting, in
accordance with the arrangements indicated in the Company’s notice
of meeting that will be published in the BALO official bulletin of
legal announcements on September 25, 2020.
All the preparatory documents are available from the Company on
request and are also available on the Company’s website (in the
General Assembly subsection of the Investors section).
For further information on the financing line via the reserved
issuance of bonds convertible into ordinary shares to which a share
subscription warrant is attached (the warrants and, together with
the shares to which they are attached, the equity subscription
warrants or “ABSA” and, with the convertible notes, the convertible
notes with equity warrants or “OCABSA”) in favor of Winance, please
refer to the Company’s press release of June 15, 2020.
For guidance purposes, and based on Genomic Vision’s share price
of €0.34 on September 21, 2020, the conversion of all the notes
(representing total financing of €12 million) and the exercise of
all the warrants would result in the issuance of a total of
51,724,137 new ordinary shares. A shareholder currently holding 1%
of the Company’s share capital would then hold 0.48% of its share
capital.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Based near Paris, in Bagneux, the Company has
approximately 30 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 29, 2019 filed with the AMF under reference
number R19-004, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
1 As a reminder, that resolution asked the Shareholders’ Meeting
to grant the Board of Directors the power to undertake a capital
increase via the issuance of convertible notes with warrants
(OCABSA) with shareholders’ preemptive rights waived in favor of
Winance within the framework of a convertible bond financing line
for a nominal amount of €12 million in 12 equal tranches.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200922005894/en/
Genomic Vision Dominique Rémy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com Ulysse Communication
Press Relations Bruno Arabian Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com NewCap Investor
Relations & Strategic Communications Tel.: +33 1 44
71 94 94 gv@newcap.eu
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024